Traditional antibacterial compounds in phase-I trials (Table 
bacterial infections, critically ill
BACTERIAL INFECTIONS, CRITICALLY ILL
SPR206 (MRX-8 (IV) is another polymyxin analog being developed by MicuRx (Hayward, CA, USA and Shanghai, People’s Republic of China) against G-ve bacteria [QPX-9003 (RG6319 (administration route not disclosed) is an inhibitor of LepB, which is an Zifanocycline (Apramycin (PLG0206 (PL-18 (Murepavadin (TXA709 (RG6006 (RO7223280, Abx MCP; IV) is being developed by Roche (Basel, Switzerland) and a phase-I trial (NCT05614895) was started in December 2022 in critically ill participants with bacterial infections using IV administration. RG6006 will be developed as a treatment for BWC0977 (